Compare Peloton Interactive Inc (PTON) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance

Peloton (PTON) trades at $5.06, down 1.56% today, showing mixed technical signals with a bullish overall rating but bearish moving averages. The company achieved its first profitable year in 2026 with $63M net income, though Q3 2026 earnings are pending. Revenue declined from $3.6B in 2022 to $2.4B in 2026, but profitability improved significantly with net margin turning positive. Recent product launches include new treadmills and AI features, signaling ongoing turnaround efforts.

PTON presents a speculative opportunity with analyst consensus price target of $8.00 (58% upside) and 50% buy ratings. Key risks include declining subscriber counts, high debt levels, and competitive pressures. The stock's valuation appears reasonable with P/S of 0.93, but negative shareholder equity and volatile cash flow history warrant caution. Near-term catalyst will be Q3 2026 earnings results versus expectations of $0.1098 EPS.

Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.

The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.